Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhuochuming® 3+T&E vs 3+PRN in Treatment-naïve DME
NCT07612904Phase 4Not yet recruiting
- Sponsor
- Dalian Third People's Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Dalian Third People's Hospital. Primary endpoint: Change in Best-Corrected Visual Acuity at 52 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07612904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612904.